Nascent Biotech

About:

Nascent Biotech is a biotechnology company building a portfolio of innovative therapeutic antibodies.

Website: http://www.nascentbiotech.com/

Top Investors: National Institutes of Health, BioRay Pharmaceuticals

Description:

Nascent Biotech is a biotechnology company building a portfolio of innovative therapeutic antibodies. The innate ability of the intelligence of the natural human immune system to generate a cancer-specific response combined with NBI’s technical skills opens the door for immunologically based therapeutics for human cancer. NBI is using and developing human antibodies and cytokine responses obtained from the innate natural human immune response as a drug discovery platform for identifying new antibodies and antigens for commercialization. Nascent Biotech's technology portfolio is based upon the natural human immune system, uniquely utilizing the immune system’s innate capabilities and selectivity to produce effective immune-boosting and regulation biomolecules. Their insight into the natural human immune response defines important targets for therapeutic intervention thus enabling the rapid development of new classes of safe, non-toxic, and specific biological drugs for use in the clinic.

Total Funding Amount:

$3.92M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Diego, California, United States

Founded Date:

2008-01-01

Founders:

Jonathan Sprent, Mark C. Glassy, Onur Boyman

Number of Employees:

1-10

Last Funding Date:

2022-02-23

IPO Status:

Public

Industries:

© 2025 bioDAO.ai